Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors — FIH

Locally Advanced/Metastatic Solid Tumors Clinical Trial

Official title:
First-in-human (FIH), Open-Label, Phase 1a (Dose Escalation)/Phase 1b (Expansion Cohort) Trial of BJ-001 as a Single Agent and in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Solid Tumors

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of BJ-001, a human IL-15 fusion protein, administered via subcutaneous injections, as a single agent and in combination with pembrolizumab in adult patients with Locally Advanced/Metastatic Solid Tumors

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Locally Advanced/Metastatic Solid Tumors
Neoplasms

Clinical Trial Details

NCT number	NCT04294576
Study type	Interventional
Source	BJ Bioscience, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	December 4, 2019
Completion date	October 22, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05801237` - PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor	Phase 1/Phase 2
Active, not recruiting	`NCT06130722` - First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study	Phase 1
Completed	`NCT04914351` - HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours	Phase 1
Completed	`NCT05800249` - PE0116 Injection in Treatment of Patients With Advanced Solid Tumours	Phase 1
Not yet recruiting	`NCT06414460` - Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors	Phase 1